Guardant Health, Inc., a main precision oncology company, today documented a lawsuit against Natera, Inc. for false advertising, unfair competition, and unlawful trade practices, identifying with misleading statements Natera has made about its own products and the performance of Guardant Health’s new oncology test, Guardant Reveal?. Guardant Health asked the federal court in San Francisco, California for an order keeping Natera from proceeding to offer these false or misleading expressions and requiring Natera to make corrective moves.
Guardant Health’s new introduction of Guardant Reveal?, the first blood-just fluid biopsy test to recognize residual and recurrent disease in beginning phase cancer survivors, addresses a significant clinical forward leap for the 1.5 million beginning phase colorectal cancer survivors in the U.S.1 Colorectal cancer is the subsequent driving reason for cancer demise in the U.S.2 The Guardant Reveal? test identifies circling tumor DNA (ctDNA) from a basic blood draw and is done after surgery to distinguish patients with residual disease who may profit most from adjuvant therapy and surveillance. The test can likewise identify repeat months sooner than current standard-of-care techniques, for example, carcinoembryonic antigen tests or imaging.3-8 Guardant Health’s strategy for ctDNA detection is tremendously unique in relation to Natera’s Signatera test, which requires a tissue-biopsy.9
The protest claims that Natera is misleading healthcare suppliers about the performance of the Guardant Reveal? test by recommending the test is incorrect and/or harsh, and sub-par compared to Signatera?. As an immediate outcome, colorectal cancer patients are botching openings for insignificant residual disease (MRD) detection and repeat checking, and the specialist advantages of guided treatment decisions. “Guardant Health trusts it is crucial that clinicians get exact and honest data, as this effects possibly life-saving patient treatment decisions. We additionally accept that organizations in the cancer diagnostics business should have patient consideration as their central mission and ought not distort clinical science. At the point when they do, we accept that quick corrective action is required,” said John Saia, Senior Vice President, General Counsel and Corporate Secretary at Guardant Health.